About RhoGAM® Brand
For centuries, women with Rh-negative blood experienced the heartbreak of mysteriously losing baby after baby to a condition known as Hemolytic Disease of the Newborn, or HDN. Many of these women gave birth to a healthy first child, only to experience subsequent pregnancies that ended in miscarriage, stillbirth, or birth to babies with anemia, jaundice or other serious health problems.
Prior to the development of RhoGAM®, it is estimated that 10,000 babies in the U.S. were lost annually to HDN every year – more than two dozen each day. Desperate for an effective treatment to overcome the disease, physicians resorted to administering blood transfusions to babies still in the womb, or conducting complete exchange transfusions after birth.
RhoGAM® was developed by researchers at Columbia University in New York and the Ortho Research Foundation (now Ortho Clinical Diagnostics) in Raritan, NJ. The American College of Obstetrics and Gynecology has hailed RhoGAM® as one of the top achievements in 50 years of women’s health.
Since the discovery of RhoGAM® Rho(D) Immune Globulin (Human) in 1968, Hemolytic Disease of the Newborn has been virtually eliminated in the developed world. Millions of doses of RhoGAM® have been administered since its development and Ortho Clinical Diagnostics, a Johnson & Johnson company, has provided 39 years of uninterrupted product supply.
Register to win a gift basket
Complete Prescribing Information for RhoGAM® Ultra-Filtered PLUS